Literature DB >> 11741233

Stereoselective pharmacokinetics of ifosfamide in male and female rats.

J J Wang1, H Lu, K K Chan.   

Abstract

The stereoselective pharmacokinetics of ifosfamide (IF) were investigated in male and female Sprague-Dawley rats. Following intravenous administration of IF deuterium-labeled pseudoracemates into rats at 40 mg/kg, IF enantiomers and their metabolites, 4-hydroxyIF (HOIF), N2-dechloroethylIF (N2D), N3-dechloroethylIF (N3D), and isophosphoramide mustard (IPM) were quantitated in plasma and urine using gas chromatographic-mass spectrometry techniques with appropriately deuterium-labeled analogs as the internal standards. In addition, the intrinsic clearances of IF isomers in rat liver microsomes were estimated by the in vitro metabolism study. Following drug administration in male rats, (R)-IF exhibited a lower area under the curve value and a shorter half-life of 34.2 minutes than (S)-IF, which gave a half-life of 41.8 minutes. In female rats, the half-lives of (R)- and (S)-IF were found to be 62.1 and 75.1 minutes, respectively, significantly longer than those in male rats. No change in volume of distribution or renal clearance for IF enantiomers in all rats was observed, and the protein binding value was low, with no enantioselectivity. Both in vitro and in vivo studies showed that metabolism of (R)-IF proceeded in favor of the 4-hydroxylation pathway, whereas (S)-IF preferentially underwent N2- and N3-dechloroethylation. The observed stereoselectivity and gender difference in pharmacokinetics of IF in the rat are mainly attributed to its stereoselective metabolism.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11741233      PMCID: PMC2751031          DOI: 10.1208/ps020217

Source DB:  PubMed          Journal:  AAPS PharmSci        ISSN: 1522-1059


  26 in total

1.  Role of cytochrome P450 in oxazaphosphorine metabolism. Deactivation via N-dechloroethylation and activation via 4-hydroxylation catalyzed by distinct subsets of rat liver cytochromes P450.

Authors:  L Yu; D J Waxman
Journal:  Drug Metab Dispos       Date:  1996-11       Impact factor: 3.922

2.  Enantiomers of cyclophosphamide and iphosphamide.

Authors:  P B Farmer
Journal:  Biochem Pharmacol       Date:  1988-01-01       Impact factor: 5.858

3.  Effects of phenobarbital on stereoselective metabolism of ifosfamide in rats.

Authors:  H Lu; J J Wang; K K Chan; D Young
Journal:  Drug Metab Dispos       Date:  1998-05       Impact factor: 3.922

Review 4.  Importance of drug enantiomers in clinical pharmacology.

Authors:  K Williams; E Lee
Journal:  Drugs       Date:  1985-10       Impact factor: 9.546

5.  Dechloroethylation of ifosfamide and neurotoxicity.

Authors:  M P Goren; R K Wright; C B Pratt; F E Pell
Journal:  Lancet       Date:  1986-11-22       Impact factor: 79.321

6.  Enantioselective distribution of verapamil and norverapamil into human and rat erythrocytes: the role of plasma protein binding.

Authors:  M A Robinson; R Mehvar
Journal:  Biopharm Drug Dispos       Date:  1996-10       Impact factor: 1.627

7.  A simple integrated method for drug and derived metabolite kinetics. An application of the statistical moment theory.

Authors:  K K Chan
Journal:  Drug Metab Dispos       Date:  1982 Sep-Oct       Impact factor: 3.922

8.  Role of CYP2B6 and CYP3A4 in the in vitro N-dechloroethylation of (R)- and (S)-ifosfamide in human liver microsomes.

Authors:  C P Granvil; A Madan; M Sharkawi; A Parkinson; I W Wainer
Journal:  Drug Metab Dispos       Date:  1999-04       Impact factor: 3.922

9.  Phenytoin-induced alteration in the N-dechloroethylation of ifosfamide stereoisomers.

Authors:  M P Ducharme; M L Bernstein; C P Granvil; B Gehrcke; I W Wainer
Journal:  Cancer Chemother Pharmacol       Date:  1997       Impact factor: 3.333

10.  Stereospecific synthesis of chiral metabolites of ifosfamide and their determination in the urine.

Authors:  K Misiura; A Okruszek; K Pankiewicz; W J Stec; Z Czownicki; B Utracka
Journal:  J Med Chem       Date:  1983-05       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.